Zhu Yong-Jian, Zhou Yu-Ping, Wei Yun-Peng, Xu Xi-Qi, Yan Xin-Xin, Liu Chao, Zhu Xi-Jie, Liu Zi-Yi, Sun Kai, Hua Lu, Jiang Xin, Jing Zhi-Cheng
Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Pulmonary Vascular Disease and Thrombosis Medicine, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy Medical Sciences and Peking Union Medical College, Beijing, China.
Front Cardiovasc Med. 2021 May 21;8:628284. doi: 10.3389/fcvm.2021.628284. eCollection 2021.
The association between anticoagulation outcomes and prior history of venous thromboembolism (VTE) in chronic thromboembolic pulmonary hypertension (CTEPH) has not been established. This study aimed to compare the efficacy and safety of anticoagulation treatment in CTEPH patients with and without prior history of VTE. A total of 333 CTEPH patients prescribed anticoagulants were retrospectively included from May 2013 to April 2019. The clinical characteristics were collected at their first admission. Incidental recurrent VTE and clinically relevant bleeding were recorded during follow-up. The Cox proportional regression models were used to identify potential factors associated with recurrent VTE and clinically relevant bleeding. Seventy patients (21%) without a prior history of VTE did not experience recurrent VTE during anticoagulation. Compared to CTEPH patients without a prior history of VTE, those with a prior history of VTE had an increased risk of recurrent VTE [2.27/100 person-year vs. 0/100 person-year; hazard ratio (HR), 8.92; 95% confidence interval (CI), 1.18-1142.00; = 0.029] but a similar risk of clinically relevant bleeding (3.90/100 person-year vs. 4.59/100 person-year; HR, 0.83; 95% CI, 0.38-1.78; = 0.623). Multivariate Cox analyses suggested that a prior history of VTE and interruption of anticoagulation treatments were significantly associated with an increased risk of recurrent VTE, while anemia and glucocorticoid use were significantly associated with a higher risk of clinically relevant bleeding. This study is the first to reveal that a prior history of VTE significantly increases the risk of recurrent VTE in CTEPH patients during anticoagulation treatment. This finding should be further evaluated in prospective studies.
慢性血栓栓塞性肺动脉高压(CTEPH)患者抗凝治疗效果与既往静脉血栓栓塞症(VTE)病史之间的关联尚未明确。本研究旨在比较有和没有VTE病史的CTEPH患者抗凝治疗的疗效和安全性。回顾性纳入了2013年5月至2019年4月期间共333例接受抗凝治疗的CTEPH患者。收集了他们首次入院时的临床特征。随访期间记录偶发性复发性VTE和临床相关出血情况。采用Cox比例回归模型确定与复发性VTE和临床相关出血相关的潜在因素。70例(21%)无VTE病史的患者在抗凝治疗期间未发生复发性VTE。与无VTE病史的CTEPH患者相比,有VTE病史的患者复发性VTE风险增加[2.27/100人年 vs. 0/100人年;风险比(HR),8.92;95%置信区间(CI),1.18 - 1142.00;P = 0.029],但临床相关出血风险相似(3.90/100人年 vs. 4.59/100人年;HR,0.83;95%CI,0.38 - 1.78;P = 0.623)。多因素Cox分析表明,VTE病史和抗凝治疗中断与复发性VTE风险增加显著相关,而贫血和使用糖皮质激素与临床相关出血风险较高显著相关。本研究首次揭示,VTE病史显著增加CTEPH患者抗凝治疗期间复发性VTE的风险。这一发现应在前瞻性研究中进一步评估。